在FDA不良事件报告系统数据库中对efgartigimod alfa进行真实世界的药监测研究
Yunlin Yang1, Jinfeng Liu2, Wei Wei2,3,4
1Department of Clinical Pharmacy, Shifang People's Hospital, Shifang, Sichuan, China.
Frontiers in pharmacology
|May 1, 2025
概括
使用FAERS数据评估了Efgartigimod alfa在一般化骨髓灰质炎 (gMG) 患者的安全性. 检测到一些意想不到的不良事件,如不适当的服用时间表和结石病,需要持续保持警.
科学领域:
- 药物监督 药物监督 药物监督
- 临床安全 临床安全
- 药品监管事务 药品监管事务
背景情况:
- 埃夫加尔蒂基莫德阿尔法已批准用于抗乙胆受体 (AChR) 抗体阳性成年人普遍性肌痛性肌痛症 (gMG).
- 对efgartigimod alfa在大量人群中的长期安全性数据有限.
- 营销后监测对于了解现实世界药物安全概况至关重要.
研究的目的:
- 使用现实世界的数据分析与efgartigimod alfa相关的不良事件 (AE).
- 识别临床试验中观察到的潜在安全信号以外的潜在安全信号.
- 在广泛的患者群体中评估efgartigimod alfa的营销后安全概况.
主要方法:
- 使用FDA不良事件报告系统 (FAERS) 数据库进行数据收集.
- 分析了2022年第一季度至2024年第二季度的报告,重点关注efgartigimod alfa作为主要嫌疑人.
- 在数据挖掘中使用不成比例分析来检测AE信号.
主要成果:
- 获取了3040份报告和12487份与efgartigimod alfa相关的副作用.
- 住院治疗是最常见的严重结果 (53.22%);死亡发生在8.88%的病例中.
- 检测到137个AE信号,其中包括不适当的产品服药时间表和结石病,以及与感染相关的事件.
结论:
- 该研究提供了对efgartigimod alfa.的全面营销后安全性评估.
- 强调需要持续监测与感染相关的副作用,并强调培训适当的管理.
- 建议进一步研究efgartigimod alfa和结石病之间的关联.
关键词:
公平的人是公平的.不良事件是不良事件.数据挖掘是数据挖掘的一个方法.对于efgartigimod alfa来说,这是一个非常好的方法.一般化骨髓灰质炎 (Myasthenia Gravis) 的发生.药物监督和药物监督更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.2K
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
1.8K
相关概念视频
Pharmacovigilance
735
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
735
Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
119
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
119
Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
